Praxis Precision Medicine Stock (NASDAQ: PRAX)

Praxis Precision Medicine

PRAXIS PRECISION MEDICINES I

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Praxis Precision Medicines, Inc.

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

PRAX

Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.

Praxis Precision Medicines &#39;A Diversified Player In Epilepsy Market,&#39; Analyst Sees Over 100% Stock Upside

Stuttgart,,Germany,-,07-19-2024:,Smartphone,With,Logo,Of,American,Recycling

Pre-Market Outlook

Markets

XENE

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Praxis Precision Medicines

Price Target

Praxis Precision Medicines&#39; ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

Praxis Funds Praxis Impact Large Cap Growth ETF

Praxis Funds Praxis Impact Large Cap Value ETF

Praxsyn Corp

Financing

Press Releases

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Earnings

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines to Participate in Upcoming Conferences

IONS

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Cidara Therapeutics

Cogent Biosciences

Dyne Therapeutics

Geron

Immunome

MiMedx Group

Jyong Biotech

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Verve Therapeutics

Vir Biotechnology

Zymeworks

Needham

Oppenheimer

Chardan Capital

Wedbush

HC Wainwright & Co.

Comments

Praxis Precision Medicine

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell